B
BriaCell Therapeutics Corp. (BCTX)
NCM – Real Time Price. Currency in USD
4.08
-0.08 (-1.92%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.08
-0.08 (-1.92%)
At close: May 12, 2026, 4:00 PM EDT
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
| Name | Position |
|---|---|
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
| Dr. Giuseppe Del Priore M.D., M.P.H. | Chief Medical Officer |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. William V. Williams FCPA, M.D. | CEO, President & Director |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | CFO & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-31 | 8-K | form8-k.htm |
| 2026-03-10 | 10-Q | form10-q.htm |
| 2026-03-09 | 8-K | form8-k.htm |
| 2026-02-20 | 8-K | form8-k.htm |
| 2026-02-12 | DEF 14A | formdef14a.htm |
| 2026-01-15 | 8-K | form8-k.htm |
| 2026-01-13 | S-1MEF | forms-1mef.htm |
| 2025-12-29 | 8-K | form8-k.htm |
| 2025-12-11 | 10-Q | form10-q.htm |
| 2025-12-01 | 8-K | form8-k.htm |